Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations treated in real-world conditions.

Background: OPC proved to be effective in treating end-of-dose motor fluctuations (MF) in PD patients [1,2]. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of patients treated in real-world conditions [3].

Method: OPTIPARK was a prospective, open-label, single-arm trial conducted in Germany and the UK. Patients with MF received OPC 50 mg in addition to current antiparkinsonian treatment. Primary efficacy 3-month endpoint was Clinician’s-Global-Impression-of-Change (CGI-C). Secondary efficacy endpoints included Patient’s-CGI-C (PGI-C), 8-item PD Questionnaire (PDQ-8), Unified PD Rating (UPDRS) and Non-Motor Symptoms (NMSS) scales. Safety assessments included evaluation of treatment-emergent adverse-events (TEAEs). This post-hoc analysis evaluated the influence of demographic characteristics (i.e., age and gender) in patients who completed the study for each outcome.

Results: Overall, 393 (82.4%) patients completed the 3-month endpoint (completers-set, Table 1). Of these, younger (<67.2 years-old) and female patients experienced greater very much/much improvement on CGI-C and PGI-C, when compared, respectively, to older and male patients (Table 2). Except for UPDRS-II, younger and male patients reported greater improvements on UPDRS-III, PDQ-8 and NMSS, when compared to older and female patients (Table 3). Lower incidence of TEAEs considered at least possibly related to OPC were reported for younger and male patients, when compared to older and female patients (Table 3).

Conclusion: These findings indicate that younger PD patients with MF may have an added benefit from using OPC 50 mg as adjunctive therapy to levodopa.

References: 1. Ferreira et al., Lancet Neurology 2016; 15(2):154-165. 2. Lees et al., JAMA Neurol. 2017; 74(2):197-206. 3. Reichmann et al., Transl Neurodegener. 2020;9(1):9

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/influence-of-demographic-characteristics-on-the-effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-findings-from-the-real-world-optipark-study/